01708nam a2200265   45000010005000000100015000050900009000201000041000291010008000702000158000782100083002362150017003192250040003363000132003763300542005086060028010506060040010786060038011186060028011566060020011846060030012047100075012348520011013099950122013207583  a9291681229  a7583  a20030115d2002       y0pory50      ba  aeng  aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugsfEuropean Monitoring Centre for Drugs and Drug Addiction  aLuxembourgcOffice for Official Publications of the European Communitiesd2002  a92 p.d21 cm  aImplemention of the joint actionv4  aInformação sobre European Monitoring Centre for Drugs and Drug Addiction pode ser encontrada no site: https://www.emcdda.org  aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugs. Europol-EMCDDS progress report on GHB in accordance with Article 3 of the joint action of 16 June 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs. Use of GHB as a medicinal product (EMEA). Review of the pharmacotoxicological data on gamma-hydroxybutyric acid (GHB). Sociological and criminological (Europol) evidence on the risk of GHB. Public health risk of GHB - epidemiological evidence.  aDROGAS ILÍCITAS96631  aSUBSTÂNCIAS PSICOTRÓPICAS96333  aCOOPERAÇÃO INTERNACIONAL9581  aSAÚDE PÚBLICA91370  aEUROPOL9103050  aCONSELHO DA  EUROPA96334  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION - EMCDDA95764  jDRO321  104DRO_321_00000000000000052021-12-1764435910369aDGRSPcDGRSPfDGRSP4435526872kDRO321n2021-12-17o0rMOxoferta